Press Releases Therapix Biosciences Ltd. OTC Markets

Equities

TRPXY

US88339A3023

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+27.78%	+53.33%

16/07	SciSparc Receives Nasdaq Noncompliance Notice	MT
16/07	SciSparc Seeks Patent for Obesity Drug Ingredient's Composition	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million	04:37pm	GL
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification	16/07	GL
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss	16/07	GL
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company	08/07	GL
SciSparc : Report Of Foreign Private Issuer Form 6 K	15/06	PU
SciSparc Secures Strategic Advantage with Grant of European Patent	31/05	GL
SciSparc to Acquire AutoMax	11/04	GL
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research	21/03	GL
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada	18/03	GL
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada	18/03	AQ
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial	14/03	GL
SciSparc : MitoCareX Update - Form 6-K	13/03	PU
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure	12/03	GL
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure	12/03	AQ
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder	08/03	GL
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder	08/03	AQ
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe	07/03	GL
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe	07/03	AQ
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology	07/03	GL
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing	29/02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Therapix Biosciences Ltd. OTC Markets

Equities

TRPXY

US88339A3023

Press Releases

Filters